PMD Device Solutions AB

Equities

PMDS

SE0021513645

Biotechnology & Medical Research

Delayed Nasdaq Stockholm Other stock markets 08:12:58 05/06/2024 BST			5-day change	1st Jan Change
6.75 ^SEK	-2.17%		+1.50%	-38.88%

05-13	PMD Device Solutions AB Signs Letter of Intent for the Coala-Life Technology for SEK 2 Million Per Year with Royalties	CI
05-02	PMD Device Solutions Agrees on Head of Terms to License the Coala-Life Technology	CI

Promore Pharma AB Announces Board Changes

October 17, 2019 at 12:00 pm

Promore Pharma AB (publ) announced the composition of the Nomination Committee for the Annual General Meeting 2020, which will be held on Tuesday 26 May 2020. The company appointed Göran Pettersson, Chairman of the Board, David Sundin, representing Midroc New Technology, Graham Fagg, representing Rosetta Capital and Per Lönn, representing PharmaResearch Products to the committee.

Latest news about PMD Device Solutions AB

PMD Device Solutions AB Signs Letter of Intent for the Coala-Life Technology for SEK 2 Million Per Year with Royalties	05-13	CI
PMD Device Solutions Agrees on Head of Terms to License the Coala-Life Technology	05-02	CI
PMD Device Solutions AB (OM:PMDS) acquired Coala Life Inc from Coala-Life Group AB for SEK 3.6 million.	04-10	CI
PMD Device Solutions to Purchase Coala-Life Group's US Unit	04-09	MT
PMD Device Solutions AB (OM:PMDS) intends to acquire Coala Life Inc. from Coala-Life Group AB.	04-08	CI
PMD Device Solutions AB Begins Preparation for First German Hospital Pilot	03-25	CI
PMD Device Solutions to Complete Reverse Stock Split; Shares Soar	01-29	MT
Promore Pharma AB will Change its Ticker to PMDS from PROMO	01-17	CI
Promore Pharma AB will Change its Name to PMD Device Solutions AB	01-17	CI
Promore Pharma AB Announces Board Appointments	12-29	CI
Pmd Device Solutions AB completed the acquisition of Promore Pharma AB (OM:PROMO) in a reverse merger transaction.	12-28	CI
Transcript : Promore Pharma AB - Special Call	12-18
Promore Pharma to Buy PMD Device Solutions via Reverse Acquisition; Stock Skyrockets	11-29	MT
Pmd Device Solutions AB intends to acquire Promore Pharma AB (OM:PROMO) in a reverse merger transaction for approximately SEK 130 million.	11-28	CI
Promore Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
Promore Pharma Enters Voluntary Liquidation	12/10/23	MT
Promore Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23	CI
Promore Pharma AB Announces CFO Change	22/06/23	CI
Promore Pharma AB Announces CEO Change	22/06/23	CI
Promore Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23/05/23	CI
Promore Pharma AB Auditor Raises 'Going Concern' Doubt	08/05/23	CI
Transcript : Promore Pharma AB - Special Call	21/04/23
Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide	20/04/23	CI
Promore Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	28/02/23	CI
Promore Pharma Reaches the Clean File Milestone in its Phase II Clinical Trial with Ensereptide	27/02/23	CI

Chart PMD Device Solutions AB

Duration

Period

More charts

Company Profile

PMD Device Solutions AB is a Sweden-based biopharmaceutical company. The Company deals with research, development and production of medical technical products and equipment and related activities. It specializes in the development of therapeutic peptides for the bioactive wound care market. The Company possesses two therapeutic peptides, PXL01 and LL-37, in late stage clinical phase. The peptides are derived from human sequences that are part of innate immune system, having multiple biological functions and properties. PXL01 aims to prevent post-surgical adhesions and scars and is for clinical phase III-studies on patients performing tendon repair surgery in the hand. LL-37 aims to heal chronic wounds and is in a clinical phase IIb study on patients with venous leg ulcers and in a clinical phase IIa study on patients with diabetic foot ulcers. PMD Device Solutions AB develops and sells medical products for respiratory monitoring.

Sector

Biotechnology & Medical Research

Calendar

28/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PMD DEVICE SOLUTIONS AB	-38.88%	13.77M
VERTEX PHARMACEUTICALS INCORPORATED	+16.73%	123B
REGENERON PHARMACEUTICALS, INC.	+13.04%	107B
BIONTECH SE	-5.80%	24.01B
ARGENX SE	+2.21%	22.59B
GENMAB A/S	-10.09%	18.16B
WUXI APPTEC CO., LTD.	-40.52%	16.84B
BEIGENE, LTD.	-14.00%	16.23B
NEUROCRINE BIOSCIENCES, INC.	+1.18%	13.43B
SAREPTA THERAPEUTICS, INC.	+24.18%	11.32B

Bio Therapeutic Drugs